SI3297653T1 - Zdravljenje postbariatrične hipoglikemije z antagonisti glp-1 - Google Patents

Zdravljenje postbariatrične hipoglikemije z antagonisti glp-1

Info

Publication number
SI3297653T1
SI3297653T1 SI201631362T SI201631362T SI3297653T1 SI 3297653 T1 SI3297653 T1 SI 3297653T1 SI 201631362 T SI201631362 T SI 201631362T SI 201631362 T SI201631362 T SI 201631362T SI 3297653 T1 SI3297653 T1 SI 3297653T1
Authority
SI
Slovenia
Prior art keywords
glp
antagonists
post
treatment
bariatric hypoglycemia
Prior art date
Application number
SI201631362T
Other languages
English (en)
Inventor
Tracey L. MCLAUGHLIN
Colleen M. Craig
Original Assignee
The Board Of Trustees Of Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of Leland Stanford Junior University filed Critical The Board Of Trustees Of Leland Stanford Junior University
Publication of SI3297653T1 publication Critical patent/SI3297653T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
SI201631362T 2015-05-22 2016-05-23 Zdravljenje postbariatrične hipoglikemije z antagonisti glp-1 SI3297653T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562165743P 2015-05-22 2015-05-22
US201562254175P 2015-11-11 2015-11-11
US201662329850P 2016-04-29 2016-04-29
EP16800620.3A EP3297653B1 (en) 2015-05-22 2016-05-23 Treatment of post-bariatric hypoglycemia with glp-1 antagonists
PCT/US2016/033836 WO2016191394A1 (en) 2015-05-22 2016-05-23 Treatment of post-bariatric hypoglycemia with glp-1 antagonists

Publications (1)

Publication Number Publication Date
SI3297653T1 true SI3297653T1 (sl) 2022-01-31

Family

ID=57393681

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201631300T SI3297654T1 (sl) 2015-05-22 2016-05-23 Zdravljenje postbariatrične hipoglikemije z eksendinom(9-39)
SI201631362T SI3297653T1 (sl) 2015-05-22 2016-05-23 Zdravljenje postbariatrične hipoglikemije z antagonisti glp-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201631300T SI3297654T1 (sl) 2015-05-22 2016-05-23 Zdravljenje postbariatrične hipoglikemije z eksendinom(9-39)

Country Status (17)

Country Link
US (8) US10660937B2 (sl)
EP (4) EP3978011A1 (sl)
AU (4) AU2016267057B2 (sl)
BR (2) BR112017025000A2 (sl)
CA (2) CA3024353A1 (sl)
CL (2) CL2017002911A1 (sl)
CY (2) CY1124616T1 (sl)
DK (2) DK3297654T3 (sl)
ES (2) ES2887723T3 (sl)
HR (2) HRP20211768T1 (sl)
HU (2) HUE057301T2 (sl)
LT (2) LT3297654T (sl)
PL (2) PL3297654T3 (sl)
PT (2) PT3297654T (sl)
RS (2) RS62627B1 (sl)
SI (2) SI3297654T1 (sl)
WO (2) WO2016191395A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008085982A2 (en) 2007-01-08 2008-07-17 The Trustees Of The University Of Pennsylvania Methods and compositions for treating hypoglycemic disorders
EP3978011A1 (en) 2015-05-22 2022-04-06 The Board of Trustees of the Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
US11020484B2 (en) 2016-11-21 2021-06-01 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
US20210030847A1 (en) * 2018-01-23 2021-02-04 Xeris Pharmaceuticals, Inc. Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
GB201816639D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd GLP-1 Receptor Antagonist
EP4233842A3 (en) * 2018-10-15 2023-10-25 Eiger Biopharmaceuticals, Inc. Avexitide for the treatment of hyperinsulinemic hypoglycemia
EP3908274A1 (en) * 2019-01-11 2021-11-17 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2024042518A1 (en) * 2022-08-21 2024-02-29 M. Arkin (1999) Ltd Glp-1 receptor antagonist and methods of use thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL176007B1 (pl) 1992-06-15 1999-03-31 Scios Inc Nowe pochodne polipeptydu GLP-1
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
JP2001501593A (ja) 1996-08-08 2001-02-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 胃腸運動を調節するための方法
US6956026B2 (en) 1997-01-07 2005-10-18 Amylin Pharmaceuticals, Inc. Use of exendins for the reduction of food intake
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1003581B1 (en) 1998-01-30 2000-11-08 Novo Nordisk A/S An injection syringe
AU758968B2 (en) 1998-12-10 2003-04-03 Agouron Pharmaceuticals, Inc. Non-peptide antagonists of GLP-1 receptor and methods of use
JP4426727B2 (ja) 1999-01-14 2010-03-03 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト製剤とその投与方法
PT1143989E (pt) 1999-01-14 2007-03-30 Amylin Pharmaceuticals Inc Exendinas para supressão de glucagon
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
JP4398644B2 (ja) * 2001-04-06 2010-01-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア ＥｒｂＢ界面ペプチド擬態およびその使用方法
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CN1968700A (zh) 2004-04-15 2007-05-23 阿尔克姆斯有限公司 聚合物基的持续释放装置
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
CN101217940B (zh) 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
EP2347762B1 (en) 2005-08-19 2019-05-08 Amylin Pharmaceuticals, LLC Exendin for treating diabetes and reducing body weight
JP2009538356A (ja) 2006-05-26 2009-11-05 アミリン・ファーマシューティカルズ，インコーポレイテッド 鬱血性心不全の治療のための組成物および方法
WO2008085982A2 (en) 2007-01-08 2008-07-17 The Trustees Of The University Of Pennsylvania Methods and compositions for treating hypoglycemic disorders
DE102007016811A1 (de) 2007-04-05 2008-10-09 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
JP5128658B2 (ja) 2007-04-05 2013-01-23 テクファーマ・ライセンシング・アクチェンゲゼルシャフト 機能的な駆動素子を備える投与装置
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2300031B1 (en) 2008-05-05 2017-09-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
WO2009158412A2 (en) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
PL2310042T3 (pl) * 2008-07-08 2013-05-31 Novartis Ag Zastosowanie pasyreotydu do leczenia endogennej hipoglikemii hiperinsulinemicznej
FI2341905T4 (fi) 2008-09-04 2023-12-04 Amylin Pharmaceuticals Llc Pitkävaikutteisia formulaatioita, joissa käytetään ei-vesipitoisia kantajia
US8846612B2 (en) 2009-04-03 2014-09-30 Nestec S.A. Promotion of healthy catch-up growth
CA2764108A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
US20130137645A1 (en) 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140256626A1 (en) 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
CA2875983A1 (en) 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3978011A1 (en) 2015-05-22 2022-04-06 The Board of Trustees of the Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
US11020484B2 (en) 2016-11-21 2021-06-01 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)

Also Published As

Publication number Publication date
PL3297654T3 (pl) 2021-12-20
US20180147261A1 (en) 2018-05-31
CL2017002913A1 (es) 2018-06-01
PT3297653T (pt) 2021-10-25
HUE057301T2 (hu) 2022-05-28
US20180117122A1 (en) 2018-05-03
US20200276272A1 (en) 2020-09-03
AU2016267052A1 (en) 2017-12-14
US20210290731A1 (en) 2021-09-23
US10660937B2 (en) 2020-05-26
PT3297654T (pt) 2021-09-06
SI3297654T1 (sl) 2021-11-30
AU2022201973A1 (en) 2022-04-14
ES2897955T3 (es) 2022-03-03
HUE055728T2 (hu) 2021-12-28
CY1125147T1 (el) 2023-03-24
CL2017002911A1 (es) 2018-05-25
EP3297654B1 (en) 2021-07-07
AU2016267057B2 (en) 2021-12-23
HRP20211285T1 (hr) 2022-01-07
US20200276271A1 (en) 2020-09-03
EP3297654A4 (en) 2018-04-11
EP3978011A1 (en) 2022-04-06
AU2022202506A1 (en) 2022-05-12
BR112017025000A2 (pt) 2018-08-07
AU2016267052B2 (en) 2022-01-20
CA3024358A1 (en) 2016-12-01
EP3297653B1 (en) 2021-09-15
AU2016267057A1 (en) 2017-12-14
WO2016191394A1 (en) 2016-12-01
US20230346890A1 (en) 2023-11-02
PL3297653T3 (pl) 2022-01-31
BR112017024997A2 (pt) 2018-07-31
DK3297654T3 (da) 2021-09-06
LT3297654T (lt) 2021-10-25
EP3936143A1 (en) 2022-01-12
EP3297653A1 (en) 2018-03-28
CA3024353A1 (en) 2016-12-01
LT3297653T (lt) 2022-01-10
US10993992B2 (en) 2021-05-04
RS62627B1 (sr) 2021-12-31
US11622995B2 (en) 2023-04-11
RS62368B1 (sr) 2021-10-29
WO2016191395A1 (en) 2016-12-01
DK3297653T3 (da) 2021-10-18
EP3297654A1 (en) 2018-03-28
US20210315974A1 (en) 2021-10-14
ES2887723T3 (es) 2021-12-27
US10639354B2 (en) 2020-05-05
CY1124616T1 (el) 2022-07-22
US20240000894A1 (en) 2024-01-04
US10993991B2 (en) 2021-05-04
US11617782B2 (en) 2023-04-04
HRP20211768T1 (hr) 2022-02-18
EP3297653A4 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
IL251741A0 (en) Co-agonists for glucagon and 1- glp receptors
HUE045575T2 (hu) Egyszer használatos fecskendõ
RS62627B1 (sr) Tretman post-bariatrijske hipoglikemije sa glp-1 antagonistima
HK1248552A1 (zh) 使用川地匹坦的治療方法
HK1244722A1 (zh) 可伸縮針式注射器
AU362192S (en) Bath
ZA201802017B (en) Novel insulin analogs and use thereof
TWD174559S (zh) 浴缸之部分
IL251013A0 (en) Implantable electrode
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
HK1250329A1 (zh) 使用祖細胞治療眼部病症
PT3188778T (pt) Injetor tipo caneta
GB201412010D0 (en) Treatment of hypertransaminasemia
RS60316B1 (sr) Lečenje dijabetesa tipa 1 korišćenjem glp-1 i anti-il-21
HUE048860T2 (hu) 1-es típusú cukorbetegség kezelése GLP-1 és anti-IL-21 alkalmazásával
GB201513922D0 (en) Treatment of hyperpigmentation
GB201417423D0 (en) Bath
GB201400235D0 (en) Treatment
GB201400239D0 (en) Treatment
GB201400238D0 (en) Treatment